Diligence memo · auto-generated · as of July 2, 2026

Pediapharm Inc.

Pediapharm Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Pediapharm Inc. operates in Pharmaceuticals, based in VERDUN.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Pediapharm Inc. has raised $7.7M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $7.7M on 2018-10-11.

Most recent recorded round closed around 2018-10-11.

Valuation (modeled)modeled

Provath models Pediapharm Inc. at approximately $238M (range $8.8M–$1.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.33× the median modeled value of Series A Pharmaceuticals companies in 2016–2018 (88 peers) — value vs value, same stage and era. Within the normal band (133% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 7.7 yr ago; this sector typically re-raises about every 13 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 49% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 71% of those peers.

Closest niche peers: Arbutus Biopharma Corp, Rvc 360, Llc, Sterrx, Llc, Ribometrix, Inc., Neuraltus Pharmaceuticals, Inc..

Peoplefiled

6 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.